{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:44:40Z","timestamp":1770223480052,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.cpcardiol.2017.12.002","type":"journal-article","created":{"date-parts":[[2017,12,16]],"date-time":"2017-12-16T18:00:18Z","timestamp":1513447218000},"page":"294-304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Neurohormonal Imbalance: A Neglected Problem\u2014And Potential Therapeutic Target\u2014In Acute Heart Failure"],"prefix":"10.1016","volume":"43","author":[{"given":"Steven R.","family":"Goldsmith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley A.","family":"Bart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ileana L.","family":"Pin~a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2017.12.002_bib1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jacc.2008.10.041","article-title":"Acute heart failure syndromes","volume":"53","author":"Gheorghiade","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0735-1097(02)02896-6","article-title":"Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system","volume":"41","author":"Adamson","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib3","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0140-6736(11)60101-3","article-title":"Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial","volume":"377","author":"Abraham","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.pcad.2009.11.005","article-title":"Congestion as a therapeutic target in acute heart failure syndromes","volume":"52","author":"Goldsmith","year":"2010","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib5","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMe1401231","article-title":"Lessons from the TOPCAT trial","volume":"370","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib6","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11897-013-0175-3","article-title":"Vasopressin receptor antagonists: from pivotal trials to current practice","volume":"11","author":"Kalra","year":"2014","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jchf.2014.09.003","article-title":"Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure","volume":"3","author":"Mentz","year":"2015","journal-title":"Heart Fail"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1161\/CIRCHEARTFAILURE.112.970012","article-title":"Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial","volume":"6","author":"Lanfear","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib10","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa0706824","article-title":"Cardiac troponin and outcome in acute heart failure","volume":"358","author":"Peacock","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-103-1-1","article-title":"Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis","volume":"103","author":"Francis","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib12","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1161\/CIRCHEARTFAILURE.113.000828","article-title":"Decongestive therapy and renal function in acute heart failure: time for a new approach?","volume":"7","author":"Goldsmith","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib13","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1601895","article-title":"Effect of ularitide on cardiovascular mortality in acute heart failure","author":"Packer","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","article-title":"Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial","volume":"381","author":"Teerlink","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib15","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1161\/hc1102.105264","article-title":"BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy","volume":"105","author":"Gottlieb","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib16","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/0002-9149(89)90588-2","article-title":"Attenuation of the pressor response to intravenous furosemide by angiotensin converting enzyme inhibition in congestive heart failure","volume":"64","author":"Goldsmith","year":"1989","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib17","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.jacc.2004.04.059","article-title":"Furosemide and the progression of left ventricular dysfunction in experimental heart failure","volume":"44","author":"McCurley","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1161\/CIRCHEARTFAILURE.108.821785","article-title":"Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?","volume":"2","author":"Felker","year":"2009","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib19","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/0735-1097(93)90685-T","article-title":"Isolated ultrafiltration in moderate congestive heart failure","volume":"21","author":"Agostoni","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib20","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.jacc.2005.05.098","article-title":"Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial","volume":"46","author":"Bart","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/eurjhf\/hfq207","article-title":"Effects of ULTRAfiltration vs DIureticS on clinical, biohumoral and haemodynamic variables in patients with deCOmpensated heart failure: the ULTRADISCO study","volume":"13","author":"Giglioli","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11936-006-0051-5","article-title":"The role of ultrafiltration in the management of heart failure","volume":"8","author":"Costanzo","year":"2006","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib23","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1056\/NEJMoa1210357","article-title":"Ultrafiltration in decompensated heart failure with cardiorenal syndrome","volume":"36","author":"Bart","year":"2012","journal-title":"New Engl J Med"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib24","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.cardfail.2008.06.003","article-title":"Efficacy and safety of the vasopressin V1A\/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study","volume":"14","author":"Goldsmith","year":"2008","journal-title":"J Card Fail"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib25","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cardfail.2016.02.007","article-title":"Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction","volume":"22","author":"Matsue","year":"2016","journal-title":"J Card Fail"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib26","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome Trial","volume":"297","author":"Konstam","year":"2007","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib27","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2016.09.004","article-title":"Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure","volume":"69","author":"Felker","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib28","doi-asserted-by":"crossref","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","article-title":"Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure","volume":"290","author":"Costello-Boerrigter","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib29","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cardfail.2011.08.005","article-title":"A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction","volume":"17","author":"Udelson","year":"2011","journal-title":"J Card Fail"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ehf2.12088","article-title":"Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure","volume":"3","author":"Jujo","year":"2016","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib31","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1388-9842(03)00163-6","article-title":"Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)","volume":"5","author":"Cohn","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib32","first-page":"H628","article-title":"Sensitization of cardiac receptors (vagal afferents) by intracoronary acetylstrophanthidin","volume":"239","author":"Thames","year":"1980","journal-title":"Am J Physiol"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib33","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/0735-1097(92)90185-P","article-title":"Effect of digitalis on norepinephrine kinetics in congestive heart failure","volume":"20","author":"Goldsmith","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib34","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1161\/01.CIR.73.4.615","article-title":"Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity","volume":"73","author":"Hasking","year":"1986","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib35","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jacc.2008.03.048","article-title":"Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program","volume":"52","author":"Fonarow","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib36","doi-asserted-by":"crossref","first-page":"e004675","DOI":"10.1161\/JAHA.116.004675","article-title":"Initiation, continuation, or withdrawal of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers and outcomes in patients hospitalized with heart failure with reduced ejection fraction","volume":"6","author":"Gilstrap","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cpcardiol.2017.12.002_bib37","first-page":"620","article-title":"Get the right balance: a novel vasopressin receptor antagonist equally blocks human V1a and V2 receptors and inhibits the release of plasminogen activator inhibitor-1 from cardiomyocytes","volume":"37","author":"Kolkhof","year":"2016","journal-title":"Eur Heart J"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280617301883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280617301883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,16]],"date-time":"2018-06-16T11:06:50Z","timestamp":1529147210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280617301883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0146280617301883"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2017.12.002","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurohormonal Imbalance: A Neglected Problem\u2014And Potential Therapeutic Target\u2014In Acute Heart Failure","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2017.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}